Adverum Biotechnologies Inc Forecast, price target & analysts
Adverum Biotechnologies Inc Target price 2025 - Analyst rating & recommendation
Adverum Biotechnologies Inc Classifications & Recommendation:
Adverum Biotechnologies Inc Price Target
| Target Price | $19.33 |
| Price | $4.26 |
| Potential |
353.83%
register free of charge
|
| Number of Estimates | 3 |
|
3 Analysts have issued a price target Adverum Biotechnologies Inc 2026 .
The average Adverum Biotechnologies Inc target price is $19.33.
This is
353.83%
register free of charge
$32.00
651.17%
register free of charge
$10.00
134.74%
register free of charge
|
|
| A rating was issued by 4 analysts: 3 Analysts recommend Adverum Biotechnologies Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Adverum Biotechnologies Inc stock has an average upside potential 2026 of
353.83%
register free of charge
|
Sales and Margin forecast 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Revenue Million $ | 3.60 | 1.00 |
| 72.22% | ||
| EBITDA Margin | -3,281.94% | -10,900.00% |
| 232.12% | ||
| Net Margin | -6,713.78% | -10,004.80% |
| 49.02% |
4 Analysts have issued a sales forecast Adverum Biotechnologies Inc 2024 . The average Adverum Biotechnologies Inc sales estimate is
This results in the following potential growth metrics:
1 Analyst has issued an EBITDA forecast Adverum Biotechnologies Inc 2024 . The average Adverum Biotechnologies Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
EBITDA Margin
| 2023 | -3,281.94% | |
|---|---|---|
| 2024 |
-10,900.00%
232.12%
Unlock
|
|
2 Adverum Biotechnologies Inc Analysts have issued a net profit forecast 2024. The average Adverum Biotechnologies Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Net Margin
| 2023 | -6,713.78% | |
|---|---|---|
| 2024 |
-10,004.80%
49.02%
Unlock
|
|
Earnings per share, P/E ratio and EV/sales Estimates 2024, 2025 to 2028
| Dec '23 |
2024 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -11.62 | -4.81 |
| 25.37% | 58.61% | |
| P/E | negative | |
| EV/Sales | 8.64 |
2 Analysts have issued a Adverum Biotechnologies Inc forecast for earnings per share. The average Adverum Biotechnologies Inc EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2024, the Adverum Biotechnologies Inc stock is valued at an EV/Sales of
This results in the following potential growth metrics and future valuations:
EV/Sales
| Current | 8.64 | 88.56% |
|---|---|---|
| 2024 |
8.64
0.00%
Unlock
|
|
P/S ratio
| Current | 88.62 | 8.71% |
|---|---|---|
| 2024 |
88.62
0.00%
Unlock
|
|
Adverum Biotechnologies Inc...
Current Adverum Biotechnologies Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Nov 19 2024 |
| RBC Capital |
Locked
➜
Locked
|
Locked | Nov 05 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Nov 19 2024 |
|
Locked
RBC Capital:
Locked
➜
Locked
|
Nov 05 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
